Monitoring SPRY open interest helps you see where real money is positioned on ARS Pharmaceuticals Inc's options and which strikes are attracting the most commitment from traders. ARS Pharmaceuticals Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor SPRY options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising SPRY options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect ARS Pharmaceuticals Inc to settle.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where SPRY open interest is concentrated. Our scanner maps ARS Pharmaceuticals Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade ARS Pharmaceuticals Inc's options open interest as the signal it is, not as an afterthought.
